Cecile Alanio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8514991/publications.pdf

Version: 2024-02-01

32 papers 4,670 citations

331259 21 h-index 433756 31 g-index

41 all docs

41 docs citations

times ranked

41

11485 citing authors

#	Article	IF	CITATIONS
1	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood, 2022, 139, 1026-1038.	0.6	67
2	Cytomegalovirus Latent Infection is Associated with an Increased Risk of COVID-19-Related Hospitalization. Journal of Infectious Diseases, 2022, 226, 463-473.	1.9	39
3	Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old. EBioMedicine, 2022, 76, 103852.	2.7	17
4	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature, 2022, 602, 503-509.	13.7	369
5	Signaling Through Fcî³RIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19. Frontiers in Immunology, 2022, 13, 834988.	2.2	26
6	Immunologic Features in <i>De Novo</i> and Recurrent Glioblastoma Are Associated with Survival Outcomes. Cancer Immunology Research, 2022, 10, 800-810.	1.6	9
7	Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nature Medicine, 2022, 28, 1167-1177.	15.2	112
8	CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncology, The, 2021, 22, 118-131.	5.1	177
9	Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19. Science Immunology, 2021, 6, .	5.6	152
10	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell, 2021, 184, 1858-1864.e10.	13.5	332
11	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	15.2	365
12	Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways. Cell Reports Medicine, 2021, 2, 100262.	3.3	26
13	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 4574-4586.	3.2	82
14	Subsetting the subsets: Heterogeneity and developmental relationships of T cells in human tumors. Science Immunology, 2021, 6, .	5.6	3
15	Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial. , 2021, , .		O
16	Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells. Blood, 2021, 138, 166-166.	0.6	2
17	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science, 2020, 369, .	6.0	1,280
18	Exploration of T-Cell Diversity Using Mass Cytometry. Methods in Molecular Biology, 2020, 2111, 1-20.	0.4	4

#	Article	IF	CITATIONS
19	A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals. Microbiome, 2019, 7, 130.	4.9	101
20	Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Nature Immunology, 2018, 19, 302-314.	7.0	205
21	CXCR3/CXCL10 Axis Shapes Tissue Distribution of Memory Phenotype CD8+ T Cells in Nonimmunized Mice. Journal of Immunology, 2018, 200, 139-146.	0.4	23
22	Human thymopoiesis is influenced by a common genetic variant within the $\langle i \rangle$ TCRA-TCRD $\langle i \rangle$ locus. Science Translational Medicine, 2018, 10, .	5.8	33
23	Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Medicine, 2018, 10, 59.	3.6	113
24	Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. Journal of Hepatology, 2017, 67, 1334-1339.	1.8	32
25	Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection. Blood, 2016, 128, 4898-4898.	0.6	0
26	The Milieu Intérieur study â€" An integrative approach for study of human immunological variance. Clinical Immunology, 2015, 157, 277-293.	1.4	71
27	Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients. ELife, 2015, 4, .	2.8	63
28	PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer. Cancer Research, 2013, 73, 128-138.	0.4	554
29	Tracking Antigen-Specific CD8+ T Cells Using MHC Class I Multimers. Methods in Molecular Biology, 2013, 960, 309-326.	0.4	2
30	Enumeration of human antigen–specific naive CD8+ T cells reveals conserved precursor frequencies. Blood, 2010, 115, 3718-3725.	0.6	155
31	Association between myeloid malignancies and acquired deficit in protein 4.1R: A retrospective analysis of six patients. American Journal of Hematology, 2008, 83, 275-278.	2.0	17
32	Modulation of Macrophage Activation State Protects Tissue from Necrosis during Critical Limb Ischemia in Thrombospondin-1-Deficient Mice. PLoS ONE, 2008, 3, e3950.	1.1	64